We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

61 hedge funds and large institutions have $566M invested in Kalaris Therapeutics in 2020 Q3 according to their latest regulatory filings, with 61 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1.4% more ownership

Funds ownership: 0% → 1.4% (+1.4%)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $4K

Holders
61
Holders Change
+61
Holders Change %
–
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
61
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
$4K
Net Calls
-$4K
Net Calls Change
-$4K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$197M
2
RG
Redmile Group
California
+$69.3M
3
AG
Artal Group
Luxembourg
+$69M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$40.3M
5
WP
Woodline Partners
California
+$35.4M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$1.06M +$1.14M +1,674 New
SFI
27
Susquehanna Fundamental Investments
Pennsylvania
$780K +$842K +1,233 New
DKCM
28
Davidson Kempner Capital Management
New York
$768K +$831K +1,217 New
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$746K +$805K +1,179 New
Blackstone Inc
30
Blackstone Inc
New York
$688K +$742K +1,087 New
CCM
31
CAAS Capital Management
New York
$688K +$742K +1,087 New
LCM
32
Laurion Capital Management
New York
$688K +$742K +1,087 New
ZP
33
Zimmer Partners
New York
$688K +$742K +1,087 New
Marshall Wace
34
Marshall Wace
United Kingdom
$666K +$718K +1,052 New
MFS
35
Mirabella Financial Services
United Kingdom
$462K +$499K +730 New
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$441K +$477K +698 New
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$436K +$471K +689 New
Wells Fargo
38
Wells Fargo
California
$392K +$423K +620 New
GGHC
39
Gilder Gagnon Howe & Co
New York
$380K +$410K +601 New
SSA
40
Schonfeld Strategic Advisors
New York
$366K +$395K +578 New
Deutsche Bank
41
Deutsche Bank
Germany
$332K +$359K +525 New
Jane Street
42
Jane Street
New York
$311K +$336K +492 New
AIG
43
American International Group
New York
$295K +$318K +466 New
CF
44
CNA Financial
Illinois
$295K +$319K +467 New
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$266K +$287K +420 New
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$223K +$240K +352 New
MIM
47
MetLife Investment Management
New Jersey
$221K +$238K +349 New
JP Morgan Chase
48
JP Morgan Chase
New York
$180K +$199K +291 New
MLICM
49
Metropolitan Life Insurance Company (MetLife)
New York
$151K +$163K +239 New
SO
50
STRS Ohio
Ohio
$123K +$134K +196 New
1
2
3

KLRS Hedge Fund Activity: Q3 2020 in Review

61 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q3 2020, worth a combined $566M.

Buyers outnumbered sellers: 61 funds opened new KLRS positions and 0 closed out — a net gain of 61 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $197M.

  • 61 institutional investors held Kalaris Therapeutics (KLRS) as of Q3 2020, up from 0 in Q2 2020.
  • Funds reported $566M of Kalaris Therapeutics stock for Q3 2020.
  • 61 funds opened new Kalaris Therapeutics positions in Q3 2020 and 0 closed out, a net change of +61 holders.
  • The largest Kalaris Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $197M added.

Based on aggregated 13F filings for Q3 2020.